Vorasidenib, a new drug, has performed well in prolonging progression-free survival for patients diagnosed with a subtype of glioma. Patients taking Vorasidenib could avoid disease progression for nearly 17 months, according to an international study. The study was conducted to determine whether a cancer mutation inhibitor, Vorasidenib, has the potential to suppress the growth of gliomas. The results showed that the drug target was met in almost three-quarters of patients, offering new hope for treatment. Glioma, a type of brain cancer, occurs in cells known as glial cells and is notorious for its rapid progression and low survival rate.
New Drug Shows Promise in Prolonging Progression-Free Survival for Glioma Patients
A newly developed drug, Vorasidenib, has shown promise in prolonging progression-free survival for patients with a subtype of glioma. The international study found that patients taking Vorasidenib could go nearly 17 more months without their disease progressing compared to those who took a placebo.
Latest from Blog
A new study from Bristol University's Nutrition and Behaviour Group reveals that whole foods like apples
In about a billion years, the sun's expansion will render Earth inhospitable. However, a fortuitous encounter
The 13th week of the 2023 NFL season is underway with a victory for the Cowboys.
A new report reveals that OpenAI's former board intentionally excluded Microsoft amidst ongoing conflicts with CEO
SpaceX launched Ireland's first satellite and a South Korean reconnaissance satellite today. A SpaceX Falcon 9
